Acadia Pharmaceuticals (NASDAQ: ACAD) reported an insider sale this month when Executive Vice President and Chief Financial Officer Mark C. Schneyer sold 2,709 shares of common stock on April 7, 2026. The sale price was $22.20 per share, producing total proceeds of $60,139, according to a Form 4 filing with the Securities and Exchange Commission.
The company's share price was trading near $22.10 at the time the transaction was reported. Over the past 12 months, Acadia's stock has risen about 57% from prior levels.
InvestingPro analysis cited in filings indicates that ACAD may be undervalued at current market prices, with the platform's Fair Value estimate implying potential upside from present levels.
Additional filings show related activity by Schneyer earlier in April. On April 5 he exercised options on 5,276 shares of common stock and simultaneously surrendered 5,276 Restricted Stock Units, per the disclosure.
Separately, the company reported several operational and strategic developments. The European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on Acadia's Marketing Authorization Application for trofinetide, the therapy under review for Rett syndrome. The committee cited concerns about the limited magnitude of the observed treatment effect and the clinical study's inability to capture all core symptoms.
Bank of America Securities made adjustments to its view on Acadia in light of recent events. One note indicated the firm upgraded the stock rating to Buy from Neutral, stating that the recent share-price decline was unrelated to the company’s fundamentals. In another communication, BofA reduced its price target from $31 to $29 and maintained a Neutral rating, referencing a pipeline review and the EU regulatory setback.
On the governance front, Acadia named Jonathan M. Poole to its board of directors and audit committee. His term is scheduled to expire in 2027, according to the announcement.
Taken together, the disclosures and corporate developments reflect ongoing adjustments at Acadia on both the regulatory and corporate-governance fronts while an insider sale and option exercise by the CFO have been formally reported.